ClinicalTrials.gg
CompletedNCT04289870Updated Nov 4, 2026

Innoventric Trillium™ Stent Graft First-in-Human (FIH) Study

An interventional study of Trillium™ in Tricuspid Regurgitation, sponsored by Innoventric LTD. Completed at 9 sites in 4 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Innoventric LTD · Not applicable, Interventional, and Treatment

How we know

Updated Nov 4, 2026Now CompletedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies in Tricuspid Valve Insufficiency with a site in Germany — 24 open to participants now, 31 under way, none of them phase 3. Tricuspid Valve Insufficiency · Germany.

Enrollment
22nd of 25
20 · median 60
Started
2020
with 9 others
No phase
23 of 51
7 open now
Registered
16th of 51
by date
Lead sponsor
2 of 51
Innoventric LTD

Among the 51 studies in Tricuspid Valve Insufficiency with a site in Germany, this one is the 22nd largest by enrollment of the 25 interventional ones that give a count, is one of 10 that started in 2020, is one of 23 with no phase, and was the 16th registered.

Tricuspid Valve Insufficiency

229 studies on the registry are indexed under Tricuspid Valve Insufficiency; 111 are open to participants now.

Browse Tricuspid Valve Insufficiency studies →

Open to participants now

24 of the 51 studies in Tricuspid Valve Insufficiency with a site in Germany are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 81 Tricuspid Valve Insufficiency studies recruiting now, 67 (83%) set no upper age limit and none (0%) stop at 75 or younger; 7 take children under 18; 2 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Tricuspid Valve Insufficiency with a site in Germany, or all of them as a file.
02

Study summary

A prospective, single-arm, multi-center first-in-human (FIH) study to evaluate the safety and performance of the Innoventric Trillium™ Stent Graft System.

Twenty (20) patients in 8 investigational sites will be enrolled. All enrolled study patients will be assessed at baseline, during the procedure, at discharge, after 1 month, 3 months, 6 months, 1 year, 1.5 years, 2 years, and 3 years following the index procedure.

03

Conditions studied

  • Tricuspid Regurgitation

Keywords

  • Tricuspid Valve
  • Tricuspid Valve Insufficiency
  • Tricuspid Regurgitation
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Enrolled patients must meet ALL the following criteria:

  1. Age >40 (no upper limit)
  2. Patient has TR graded as severe based on the presence of systolic hepatic vein flow reversal, and VCW≥7mm or EROA≥40mm\^2
  3. Symptomatic despite medical therapy; patient must be on diuretic therapy.
  4. Peak central venous pressure of ≥ 15mmHg
  5. The local site Heart Team determines that the patient is appropriate for transcatheter tricuspid intervention
  6. Patient is willing and able to comply with all specified study evaluations.
  7. Patient has functional classification of III or IV
  8. Patient is not eligible for standard-of-care surgical or interventional therapy assessed by the central heart team or has refused standard-of-care surgical and interventional therapy or has received standard-of-care TR therapy and remains symptomatic
  9. Patient understands the nature of the study and study requirements and is willing to provide written prior to any study-specific procedures.

Exclusion criteria

Exclusion Criteria:

Patients will be excluded from participation if ANY of the following criteria apply:

  1. Echocardiographic parameters (Any of the following):

    I. \< 20% II. Evidence of severe right ventricular dysfunction (e.g. right ventricular TAPSE \< 13.0mm) III. IVC or SVC anatomy that precludes proper device deployment and function

  2. Systolic Pulmonary Artery Pressure > 70mmHg
  3. Severe aortic, mitral, and/or pulmonic valve stenosis and/or regurgitation
  4. Active endocarditis within 90 days of the scheduled implant
  5. Significant pericardial effusion
  6. Intra-cardiac masses, thrombi, or vegetation
  7. Thrombosis of the venous system
  8. Space-consuming lesion in the heart or on the valves, thrombus, or microbial colonization of the valves
  9. Untreated coronary artery disease requiring immediate revascularization
  10. MI or known unstable angina within 30 days prior to the index procedure
  11. Any therapeutic invasive cardiac procedure within 30 days prior to the index procedure
  12. Any prior cardiac surgery, within 3 months of the index procedure
  13. Hemodynamic instability or treated with IV inotropes within 30 days of the index procedure
  14. Severe uncontrolled hypertension (SBP ≥ 180 mmHg and/or DBP ≥ 110 mm Hg)
  15. Severe uncontrolled hypotension (SBP≤80 mmHg and/or DBP≤40 mmHg)
  16. Cerebrovascular Accident (CVA) within the past 90 days
  17. Kidney dysfunction with estimated (eGFR) \< 30 ml/min/1.73 m\^2 or patient is on chronic dialysis
  18. Significant frailty (i.e. Clinical Frailty Scale© (CFS) ≥ 7) within 90 days of the scheduled implant procedure
  19. Chronic liver disease with a MELD score of 20 or greater
  20. Chronic anemia ( \< 9 g/L) not corrected by transfusion
  21. Thrombocytopenia ( count\< 100,000/mm3) or thrombocytosis (Platelet count > 750,000/mm3)
  22. Bleeding disorders or hypercoagulable state
  23. Active peptic ulcer or active gastrointestinal (GI) bleeding within 90 days of the scheduled implant
  24. to anticoagulants or antiplatelet agents
  25. Currently or history of IV drug use
  26. Pregnant or lactating; or female of with a positive pregnancy test 24 hours before any study-related radiation exposure.
  27. Inability to access the femoral vein with a 24 FR guide (e.g., DVT, occluded femoral veins).
  28. Known allergy to stainless steel, nickel, titanium, PET or contrast agents that cannot be adequately pre-medicated.
  29. Known or contraindication to procedural medications which cannot be adequately managed medically
  30. Impaired judgment
  31. Undergoing emergent or urgent treatment for tricuspid insufficiency
  32. Currently participating in another drug or device study that has not completed the primary endpoint or that clinically interferes with the endpoints of this study
  33. Co-morbid condition(s) that, in the opinion of the Investigator, limit to \< 12 months
  34. Cardiac cachexia
  35. In the judgment of the Investigator, co-morbid condition(s) that could limit the patient's ability to participate in the study, including compliance with follow-up requirements, or that could impact the scientific integrity of the study
  36. Patient is under guardianship
  37. Presence of any prosthetic device in the SVC or IVC (excluding pace-maker, ICD and CRT leads)
  38. Elevated inflammatory markers within 2 weeks of the scheduled procedure (e.g. CRP>1.5mg/dL).
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Innoventric Trillium™ Stent Graft Single Arm

    Single-arm, open label, multi-center study

    Device: Trillium™

Interventions

  • DeviceTrillium™

    Trillium™ Stent Graft for Functional Tricuspid Valve Replacement

06

What researchers measure

Primary outcomes

  1. Safety Endpoint

    Rate of device or procedure-related MAEs and Freedom from unplanned surgery or re-intervention, due to life-threatening device or procedure failure

    Time frame: Evaluated immediately after intervention, discharge and 30 days

  2. Technical performance

    Successful access, delivery, and retrieval of the Trillium delivery system, the device is anchored both in SVC and IVC.

    Time frame: Evaluated immediately after intervention

  3. Efficacy Endpoint

    TR grade as measured on the device valves (Echocardiography), or by hepatic vein systolic backflow (Echocardiography), or reduction in peak central venous pressure (Invasive hemodynamic measurement).

    Time frame: Evaluated immediately after intervention

Secondary outcomes

  1. Safety Endpoint

    Composite of all device or procedure-related MAEs.

    Time frame: Assessment at 3-month, 6-month and 1-year

  2. Efficacy Endpoint

    One or more of the following- * TR grade measured on the device valves (Echocardiography), or by hepatic vein systolic backflow (Echocardiography), or measured by a regurgitant fraction (CMR) \[at 30 days, 3-month, 6-month, and 1-year\] * Rate of hospitalizations for HF \[at 30 days, 3-month, 6-month, and 1-year\] Or one or more of the following- * Clinical Frailty Scale (CFS) \[at 30 days, 3-month, 6-month, and 1-year\] * HF functional class (NYHA) \[at 30 days, 3-month, 6-month, and 1-year\] * Six-minute walk test (6MWT) \[at 30 days, 3-month, 6-month, and 1-year\] * The Kansas City Cardiomyopathy Questionnaire (KCCQ) \[at 30 days, 3-month, 6-month, and 1-year\]

    Time frame: Assessment at 30 days, 3-month, 6-month and 1-year

Other outcomes

  1. Other Endpoints

    transthoracic echocardiography (TTE) will be performed to determine acceptable performance of the device defined as a reduction in hepatic vein systolic backflow to moderate (systolic blunting) or better. In addition, the tricuspid valve complex will be imaged to capture the following parameters for comparison to baseline: Page 46 of 118 -Confidential- 1. TR grade (qualitative) 2. Jet area 3. EROA and regurgitant volume 4. RV and LV dimensions 5. RA area/volume 6. LVEF 7. Tricuspid annular plane systolic excursion (TAPSE) 8. IVC dimensions/respiratory variations 9. Pulmonary artery pressure (PAP) 10. Right atrial pressure (RAP) 11. RV pressure 12. IVC/SVC pressure It should be noted that the above-mentioned parameters are primarily being captured for research purposes and may not be affected by the device. The following clinical and laboratory parameters will be captured for comparison to baseline values: 1. Mini Nutrition Assessment (MNA)® 2. Clinical Frailty Scale©

    Time frame: Assessment at 30 days, 3-month, 6-month and 1-year

07

Study locations

9 sites
  • OLVZ Aalst
    Aalst, Belgium
  • ZNA
    Antwerp, Belgium
  • Heart & Diabetes Center NRW
    Bad Oeynhausen, 32545, Germany
  • Herzzentrum der Charité (DHZC)
    Berlin, Germany
  • Leipzig Heart Center
    Leipzig, Germany
  • Rabin Medical Center
    Petah Tikva, 4941492, Israel
  • Hospital Clinic de Barcelona
    Barcelona, Spain
  • Hospital Universitario de Salamanca
    Salamanca, Spain
  • Hospital Alvaro Cunqueiro, Hospital Universitario de Vigo
    Vigo, Spain
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in Jul 2023, 36 months.

Of 55 industry-sponsored interventional studies with no phase under Tricuspid Valve Insufficiency, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 70. This study's 36 months is close to that.

Counting every sponsor, half of 86 studies reached it within 38 months; a quarter within 23 and three quarters within 58.

Completion moved once since we started tracking on Sep 25, 2026: Jun 2026 → Jul 2026, on Nov 4, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2020
First posted
Feb 28, 2020
StartActual
Jun 24, 2020
Primary completionActual
Jul 21, 2023
CompletionActual
Jul 14, 2026was Jun 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 4, 2026
Sites
1 site added, 1 site removed
Show site
  • Rabin Medical Center · Petah Tikva, Israel
Show 1 removed
  • Rabin Medical Center · Petah tikva, Israel
Nov 4, 2026
Study completion
Jun 2026→Jul 14, 2026 (actual)
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Active, not recruiting→Completed
    1 site added, 1 site removed
    Show site
    • Rabin Medical Center · Petah Tikva, Israel
    Show 1 removed
    • Rabin Medical Center · Petah tikva, Israel
    Study completion Jun 2026→Jul 14, 2026 (now actual)
    + 3 other changes: verification date, oversight details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04289870
Lead sponsor
Innoventric LTD
Responsible party
Sponsor
First posted
Feb 28, 2020
Start date
Jun 24, 2020
Primary completion
Jul 21, 2023
Completion
Jul 14, 2026
Last update
Nov 4, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion